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Altered triglyceride and phospholipid metabolism predates the 
diagnosis of gestational diabetes in obese pregnancy  
Samuel Furse*a, Sara L. White b, Claire L. Meeka, Benjamin Jenkins a, Clive J. Petry c, Matias C. Vieira 
b,d, Susan E. Ozannea, David B. Dunger a,c, Lucilla Poston b, Albert Koulmana . 
A Gestational diabetes (GDM), a common pregnancy complication associated with obesity and long-term health risk, is 
usually diagnosed at approximately 28w of gestation.  An understanding of lipid metabolism in women at risk of GDM could 
contribute to earlier diagnosis and treatment.  We tested the hypothesis that altered lipid metabolism at the beginning of 
the second trimester in obese pregnant women is associated with a diagnosis of GDM.  Plasma samples from 831 participants 
(16-45y, 15-18w gestation, BMI ≥30) from the UPBEAT study of obese pregnant women were used.  The lipid, sterol and 
glyceride fraction was isolated and analysed in a semi-quantitative fashion using direct infusion mass spectrometry.  A 
combination of uni-, multi-variate and multi-variable statistical analyses was used to identify candidate biomarkers in plasma 
associated with a diagnosis of GDM (early third trimester; IADPSG criteria).  Multivariable adjusted analyses showed that 
participants who later developed GDM had a greater abundance of several triglycerides (48:0, 50:1, 50:2, 51:5, 53:4) and 
phosphatidylcholine (38:5).  In contrast sphingomyelins (32:1, 41:2, 42:3), lyso-phosphatidylcholines (16:0, 18:1), 
phosphatidylcholines (35:2, 40:7, 40:10), two polyunsaturated triglycerides (46:5, 48:6) and several oxidised triglycerides 
(48:6, 54:4, 56:4, 58:6) were less abundant.  We concluded that both lipid and triglyceride metabolism were altered at least 
10 weeks before diagnosis of GDM.  Further investigation is required to determine the functional consequences of these 
differences and the mechanisms by which they arise. 
Introduction 
Gestational diabetes (GDM) occurs in 8-24% of all pregnancies 
in the UK1.  GDM is more common in obese (BMI ≥30) women, 
amongst whom approximately one third are diagnosed with the 
condition2, 3.  The increasing global prevalence of obesity4, 5 has 
therefore led to parallel trends in the diagnosis of GDM.  GDM 
is associated with adverse outcomes for mother and child 
including pre-eclampsia, complications in labour, stillbirth, fetal 
macrosomia, increased risk of later Type 2 diabetes (T2DM) for 
the mother6-10, and greater adiposity in the offspring in 
childhood and adolescence11-16.  There is also evidence from 
animal models that the over-nutrition associated with obesity 
and insulin resistance during pregnancy influences the 
metabolism of the resulting offspring17. 
Currently, GDM is diagnosed at 24-28w gestation using an 
Oral Glucose Tolerance Test (OGTT).  This test involves assessing 
the subject’s response to a glucose challenge, with fasting, +1h 
and +2h post-ingestion blood glucose measurements.  
However, the diagnostic thresholds of blood glucose 
concentration used in the diagnosis vary considerably18-21.  
Furthermore, there is mounting evidence that complications in 
labour consistent with GDM occur below some of these 
thresholds22-24, despite diagnosis and treatment25.  This, and the 
complications associated with GDM and obesity, have 
motivated a focus on earlier diagnosis and prediction.  However, 
most models employ a range of mainly non-molecular variables 
that have low sensitivity26.  This led us to consider whether 
molecular biomarkers which are not routinely measured might 
be more sensitive discriminators than clinical factors such as 
previous diagnosis of GDM, age and BMI measured alone or in 
combination with routinely measured molecular markers. 
Current evidence suggests that the concentration of glucose 
in the blood in in the first and second trimesters is not an 
accurate indicator of GDM, and that OGTT thresholds do not 
perform equivalently in earlier trimesters of pregnancy27.  This 
has led to a consensus that diagnosis of GDM using the OGTT is 
not reliable in the first and early in the second trimesters. 
However, studies of a cohort not selected for BMI found 
evidence for shifts in lipid metabolism associated with GDM, at 
a molecular level28, 29.  We have also characterised the  early 
second trimester lipoprotein profile in obese pregnancy and 
GDM and found that the abundance of VLDLs, small LDLs and 
HDLs differs in women who develop GDM compared to those 
who do not30. Collectively, this evidence suggests that both lipid 
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biosynthesis and distribution are altered in advance of a 
standard diagnosis of GDM.  Given the strong association 
between GDM and obesity, this raises the question of whether 
lipid dysregulation at a molecular level in GDM differs from that 
of obesity.  This led us to the hypothesis that the lipid 
metabolism in obese women who develop GDM is altered 
before the hyperglycaemia becomes evident. 
To test this hypothesis, we profiled the organically-soluble 
fraction (containing the lipids, glyceride and sterols) using state-
of-the-art lipidomics methods on plasma samples collected at 
15-18w gestation from the UPBEAT30-32 cohort of obese 
pregnant women.  Molecular profiling involved direct infusion 
mass spectrometry (DI-MS28, 33-37) with chip-based nanospray, in 
both positive and negative ionisation modes.  A supervised 
multi-variate analysis (sparse Partial Least Squares-Discriminant 
Analysis, sPLS-DA) followed by a student’s T-test was used to 
identify lipid molecular species that distinguished participants 
who were later diagnosed with GDM from those who did not 
develop GDM, and to identify the variables that drive this 
distinction.  Candidate biomarkers were identified using multi-
variable adjustment for confounding factors including maternal 
BMI, age, ethnicity, parity and diagnosis of pre-eclampsia. 
Experimental 
Participants 
Participants from the UK Pregnancies Better Eating and 
Activity Trial (UPBEAT; isrctn.org registration number 
89971375)38 was used for this study, characteristics are shown 
in Table 1.  UPBEAT was a multi-centre randomised controlled 
trial of a complex dietary and physical activity intervention 
designed to prevent GDM in obese women and reduce the 
number of large-for-gestational age infants.  Women with 
underlying medical conditions were excluded. The UPBEAT 
study comprised 1555 women recruited between 2009 and 
2014.  The present analysis was performed using data from 
831 women who were Caucasian, black or Asian (all), had a full 
set of data from the OGTT and a non-haemolysed plasma 
sample taken between 15 weeks 0 days’ and 18 weeks 6 days’ 
gestation (15+0 and 18+6, ~17w gestation).  All had a BMI ≥ 30 
(kg/m2) and age of 16-45 years.  Ethnicity, parity (0-7), sex of 
infant, and intervention arm were recorded and used for 
factor-based adjustment but not for stratification.  
 
Diagnosis of GDM 
The diagnoses of GDM were made according to IADPSG 
(International Association of Diabetes and Pregnancy Study 
Groups) criteria, with diagnosis based on one or more GDM-
positive plasma glucose values following an oral glucose load of 
75 g 18.  OGTTs were performed between 24+2 and 30+0 weeks’ 
(mean 27+5) gestation. 
 
Ethics  
The UPBEAT trial was granted ethical approval by the National 
Health Service Research Ethics Committee (UK Integrated 
Research Application System; reference 09/H0802/5) and all 
participants, including women aged 16 and 17 using Fraser 
guidelines, provided informed written consent 38 in compliance 
with the Declaration of Helsinki principles. 
 
Reagents and Standards 
Solvents were purchased from Sigma-Aldrich Ltd (Gillingham, 
Dorset, UK) of at least HPLC grade and were not purified 
further.  Lipid standards were purchased from Avanti Polar 
lipids (Alabaster, AL; through Instruchemie, Delfzijl, NL) and 
used without purification.  Consumables were purchased from 
Sarstedt AG & Co (Leicester, UK). 
 
Isolation of the organically-soluble fraction  
Lithium heparin plasma samples, stored at -80 °C and blinded 
to participant data and in random order were used.  Samples 
had been freeze-thawed once before the extraction in the 
present study. The lipid, triglyceride and sterol fractions were 
isolated together using a high throughput technique 
developed from existing procedures 39, 40.  Briefly, aliquots of 
plasma (25 µL) were placed along with blank and QC samples 
in the wells of a glass-coated 2.4 mL/well 96w plate (Plate+™, 
Esslab, Hadleigh, UK).  Water (100 μL, MilliQ) was added to 
each of the wells, followed by methanol (150 μL, HPLC grade, 
spiked with Internal Standards, See Table S1), followed by tert-
butyl methyl ether (TMBE, 750 μL).  The plates were then 
sealed (aluminium microplate sealing tape), agitated (10 min, 
600 rpm) and centrifuged (2 min, 3·2k × g).  A multi-channel 
pipette was used to transfer 25 μL of the organic solution to a 
glass-coated 240 μL/w 384w plate (Plate+™, Esslab, Hadleigh, 
UK). The samples were reconstituted (TBME, 25 μL and MS-mix 
[7.5 mM ammonium acetate in IPA:CH3OH (2:1)], 90 μL), and 
the plate heat-sealed and stored at -20 °C. 
 
Mass spectrometry (DI-MS) 
All samples were infused into an Exactive Orbitrap (Thermo, 
Hemel Hampstead, UK), using a Triversa Nanomate (Advion, 
Ithaca US), for direct infusion mass spectrometry (DI-MS41).  
Samples (10 μL ea.) were ionised at 1·2 kV in the positive ion 
mode.  The Exactive started acquiring data 20 s after sample 
aspiration began. The Exactive acquired data with a scan rate 
of 1 Hz (resulting in a mass resolution of 65,000 full width at 
half-maximum [fwhm] at 400 m/z). The Automatic Gain 
Control was set to 3,000,000 and the maximum ion injection 
time to10 ms. After 72 s of acquisition in positive mode the 
Nanomate and the Exactive switched over to negative mode, 
decreasing the voltage to -1·5 kV and the maximum ion 
injection time to 250 ms.  The spray was maintained for 
another 66 s, after which the analysis was stopped and the tip 
discarded, before the analysis of the next sample began.  The 
sample plate was kept at 15 °C throughout the acquisition.  
Samples were run in row order.  The instrument was operated 
in full scan mode from m/z 150–1200 Da. 
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Mass spectrometry (LC-MS) 
LCMS was run in a similar manner to recent studies29, 42, 43.  
Chromatographic separation of lipid and triglycerides was 
achieved using a Waters Acquity UPLC CSH C18 (50mm * 
2.1mm, 1.7 mm) LC-column with a Shimadzu UPLC system 
(Shimadzu UK Limited, Wolverton, Milton Keynes). The column 
was maintained at 55°C with a flow rate of 0.5 mL/min. A 
binary mobile phase system was used with mobile phase A; 
acetonitrile:water mix (6:4, respectively, with 10 mM 
ammonium formate), and mobile phase B; 
isopropanol:acetonitrile mix (9:1, respectively, with 10 mM 
ammonium formate).  The gradient profile was as follows; at 0 
minutes_40% mobile phase B, at 0.4 minutes_43% mobile 
phase B, at 0.45 minutes_50% mobile phase B, at 2.4 
minutes_54% mobile phase B, at 2.45 minutes_70% mobile 
phase B, at 7 minutes_99% mobile phase B, at 8 minutes_99% 
mobile phase B, at 8.3 minutes_40% mobile phase B, at 10 
minutes_40% mobile phase B. Mass spectrometry detection 
was performed on a Thermo Exactive orbitrap mass 
spectrometer (Thermo Scientific, Hemel Hempstead, UK) 
operating in positive ion and negative ion continuous switching 
mode. Heated electrospray source was used; the sheath gas 
was set to 40 (arbitrary units), the aux gas set to 15 (arbitrary 
units) and the capillary temperature set to 300°C. The 
instrument was operated in full scan mode from m/z 150–
1200 Da. Lipid species were identified by detecting a signal 
peak for the corresponding accurate mass at the correct 
retention time. Signals were normalized to the total 
lipid/glyceride signal for that sample.    
 
Data processing  
The lipid signals obtained were relative abundance (‘semi-
quantitative’), with the signal intensity of each lipid expressed 
relative to the total lipid signal intensity, for each individual, 
per cent (%).  The relative abundance of all species identified 
was calculated separately for positive and negative ionisation 
modes.  Raw high-resolution mass-spectrometry data were 
processed using XCMS (www.bioconductor.org) and 
Peakpicker v 2.0 (an in-house R script 37).  Lists of known 
species (by m/z) were used for both positive ion (n = 1740 incl. 
standards) and negative ion mode (n = 5075 including 
standards).  Signals that deviated by more than 9 ppm were 
discarded, as were those with a signal/noise ratio of <2 and 
those pertaining to fewer than 75% of samples.  The 
correlation of signal intensity to concentration of plasma in 
QCs (0.25, 0.5, 0.75, 1.0, 1.5×) was used to identify which lipid 
signals were linearly proportional to abundance in the sample 
type and volume used (threshold for acceptance was a 
correlation of >0.75).  The variation across analytical plates 
was corrected by batch-mean centring before the removal of 
outlier measurements (values > or < 4s.d. from the average for 
that variable).  Signals were then corrected (divided by the 
sum of signals for that sample), in order to be able to compare 
samples.  Zero values were interpreted as Not Measured. All 
signals that passed the quality control process were identified 
as their most likely molecular species and will be further called 
variables.  Importantly, signals were identified by their m/z 
and several molecular species can contribute to one signal. All 




The analysis was structured according to a prepared analysis 
plan.  Univariate analyses were carried out using Excel 2013.  
Multivariate analyses (MVA) were carried out using 
MetaboAnalyst 4.0 44.  Stata SE v. 13.0 was used for 
multivariable analyses.   
Analyses of the variables collected in positive and negative 
modes were carried out separately.  Principal component 
analyses (PCA) were used to identify sample outliers, which 
were excluded before further analysis.  sparse Partial Least 
Squares-Discriminant Analyses (sPLS-DA, an unsupervised 
MVA) were used to identify individual variables that 
distinguished the two groups.  The variables with the lowest 
probability of a false positive result (p-value, Student’s t-test) 
were regarded as the most important in driving the difference 
between groups.  The p-values were corrected using a 
Benjamini-Hochberg FDR correction based on the p-values of 
565 independent variables, with values below 0·05 after 
correction regarded as significant.  (This gave the same twenty 
variables as for a corrected Bonferroni FDR threshold based on 
565 variables, p = 0·0021).  Finally, variables that were 
identified from multivariable analysis-adjusted data were 
classed as candidate biomarkers.  Odds ratios and uncorrected 
p-values relating to association with GDM were adjusted for 
maternal age, maternal BMI, ethnicity, parity and the presence 
of pre-eclampsia.  Once again, a Benjamini-Hochberg FDR 
correction based on the p-values of 565 independent variables 
was used, with values below 0·05 after correction being 
regarded as significant.  Further adjustments for sex of infant 
and intervention arm did not materially affect the results. 
Results  
Direct infusion mass spectrometry (DI-MS) identified 215 
variables in positive ion mode and 350 in negative ion mode.  A 
combination of a sparse Partial Least Squares Discriminant 
Analysis (sPLS-DA) followed by a student’s t-test was used to 
identify which variables distinguished the groups and then the 
variables that drove the effect (Table S2, Fig. S1).  This analysis 
suggested that the abundance of several triglyceride isoforms 
(50:1, 51:5; TG fragments DG-H2O(32:0) and (38:6)) was higher 
in obese women who went on to develop GDM than those who 
did not, whilst the abundance of oxidised forms of 
commonplace TGs, TGox(54:4) and TGox(56:4) were lower.  This 
indicated that there was a significant shift in at least two aspects 
of triglyceride metabolism at least 10 weeks in advance of 
diagnosis of GDM. Several factors have been identified as 
additional risk factors for GDM that this statistical calculation 
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using unadjusted data does not account for.  These include 
adiposity, ethnicity and maternal age. Indeed, metadata for the 
participants indicated that the women who developed GDM 
were significantly older and had a higher BMI in the first 
trimester (Table 1).  After adjustment for maternal age, BMI, 
ethnicity, infant sex and parity there was an increase in the 
number, and a small change in the variables that differed 
significantly between the two groups (Fig. 1, Table S2). 
Adjusted analyses (Fig. 1, Table S3) also showed that several 
TGs were more abundant in participants who went on to 
develop GDM.  We used liquid chromatography mass 
spectrometry (LC-MS) to verify the assignments the signals.  
This also excluded certain possible isobaric species from 
identification (Table S4).  Species identified included TGs that 
comprise fatty acid residues with an odd number of carbon 
atoms and across a range of levels of unsaturation (0-5 olefin 
bonds).  At least two lighter, more poly-unsaturated TGs, 
TG(46:5) and (48:6), were less abundant in the GDM group and 
may both contain essential polyunsaturated fatty acids.    
The TGox from four commonplace TGs were also less 
abundant in participants who went on to develop GDM (48:2, 
54:4, 54:6, 58:6).  None of the (more common) TG isoforms from 
which these TGox species originate was found to have a 
significantly different abundance.  Sphingomyelins (32:1, 41:2, 
42:3) were all found to be less abundant in participants who 
went on to be diagnosed with GDM.  This was opposite to the 
shifts in abundance for cholesteryl esters (18:3 in the adjusted 
analysis, 20:5 in the unadjusted).  The pattern for 
polyunsaturated PCs was less clear, with 38:5 higher in 
abundance but 35:2, 40:7 and 40:10 lower. 
The rich but complicated pattern of shifts in phospholipid 
metabolism in the adjusted analysis raised questions about 
whether particular factors associated with GDM were 
associated with shifts in the abundance of particular species.  
We therefore carried out sensitivity analyses with respect to 
maternal age, BMI, ethnicity, parity, and intervention arm, in 
order to assess which of the candidate biomarkers identified in 
the analysis of adjusted data (Table 2) might be associated with 
classical risk factors (Table 3). 
These analyses showed that the factors (maternal BMI, age, 
parity, ethnicity) were associated with changes in the relative 
abundance of several variables.  Ethnicity and parity had a 
similar profile, associated with increased abundance of CEs, 
PC(38:5) and TGs, but decreased abundance of sphingomyelins 
and TGox.  There was some overlap between ethnicity/parity 
and maternal BMI, suggesting that some individuals may have a 
pronounced phenotype due to a summative effect. 
Discussion 
This study used detailed molecular profiling to identify 
alterations in the abundance, and thus metabolism, of plasma 
sterols, lipids and triglycerides of obese women in advance of a 
standard clinical diagnosis of GDM.  A number of variables were 
identified as having a different abundance at ~17w in women 
who were diagnosed with GDM at approximately 28w.  This 
study therefore offers evidence that lipid metabolism was 
altered at least 10 weeks before a clinical diagnosis of GDM was 
made. 
The panel of lipids identified in the present study comprised 
several phospholipids, triglycerides and oxidised triglycerides, 
and at least one cholesteryl ester, as being associated with later 
onset of the condition.  Shifts in phospholipid metabolism were 
characterised by a remodelling of polyunsaturated PCs, and a 
lower abundance of SMs, lyso-PCs and PE(38:2).  PC(38:5) was 
more abundant whereas PC(40:10) and PC(40:7) were less 
abundant, suggesting that the number of species that may 
contain essential fatty acids such as FA(20:5) (EPA) or perhaps 
DHA FA(22:6) (DHA) is reduced.  This is intriguing in the light of 
evidence that lipoprotein composition can influence the fluidity 
of cell membranes45 and also that cell membrane composition 
is reflected in that of lipoproteins46, 47.  This suggests that the 
phospholipid profile in lipoproteins is closely related to that of 
plasma membranes in vivo.  As modulation of the composition 
of lipids in hydrated systems has a profound effect on the 
physical behaviour of membranes and other assemblies that 
comprise them48-51, this raises questions about how shifts in the 
phospholipid composition of the system may alter its internal 
structures.  A lower abundance of polyunsaturated PCs 
comprising longer chains (40 carbons) is consistent with thinner 
membranes rather than less fluid ones, especially with a 
concomitant increase in the proportion of PC(38:5).  
Furthermore, a decrease in the amount of lyso-PCs disfavours 
curvature away from the water (bulging).  SM typically have 
relatively high melting transition temperatures and thus reduce 
fluidity in membranes52.  This evidence suggests that 
membranes in affected systems may be thinner and with 
modulated fluidity.  Alterations in these membrane properties 
is consistent with general evidence that membrane 
composition affects protein activity53-55.There are recognised 
relationships between membrane composition and protein 
activity in hyperglycaemia56 . In addition certain fatty acids, DAG 
and ceramide have been shown to activate certain serine 
kinases that weaken insulin signalling pathways and therefore 
cause insulin resistance57.  The studies in this area have found 
that a greater dietary intake of n-3 PUFAs is associated with 
prevention of insulin resistance and greater insulin sensitivity, 
with phosphatidylethanolamine (PE) and sphingomyelin (SM) 
being independent predictors of insulin resistance56.  The 
present study identified several species comprising PUFAs and 
three isoforms of SM that were less abundant in participants 
who were later diagnosed with GDM, providing intriguing 
possibilities for further work about the specific molecular 
mechanisms that modulate insulin signal transduction.  This 
would offer a mechanistic basis for the influence these species 
on insulin action. 
The evidence that both the lengths of fatty acid residues and 
the number of olefin bonds in them differs between GDM and 
non-GDM groups in the present study may be the result of 
changes in how fatty acids are transferred between lipids and 
triglycerides. Pregnancy represents a period in which there is 
considerable change in the expression of lipases in several 
tissues58-60.  However, this may be altered in GDM61, with 
evidence that a high  fat maternal diet (associated with obesity 
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and thus GDM)62 methylation of DNA63 and even the abundance 
of lipase inhibitor(s)64 affecting the lipase expression measured. 
The change in expression of placental endothelial lipase (PEL) is 
unclear at present, with conflicting results as to whether this 
increases in GDM65, 66.  As PEL hydrolyses fatty acids from 
triglycerides that enter the placenta, changes in its expression 
may have a profound effect on the rate of transfer of FAs from 
the mother’s circulation to that of the fetus.  This has been 
observed through an association between placental lipoprotein 
lipase activity being positively associated with adiposity of the 
infant67.  At present there are no studies that link particular lipid 
or triglyceride species to individual lipases or their expression, 
and thus a focused study is required to investigate that. 
Similarly, fatty acid transporters may play a role in GDM, 
with several recent studies in this area68-70.  One recent report 
has shown that MFSD2a, a transporter for the essential fatty 
acid DHA (FA(22:6)), found in both placenta and the CNS71, 72, 
may be lower in GDM pregnancies and thus offers a possible 
mechanism for the lower availability of DHA in GDM73.  
However, here too, focused study incorporating both labelled 
species and appropriate enzymology are not yet available. 
Triglyceride metabolism was also modulated in advance of a 
diagnosis of GDM, with the most polyunsaturated species (46:5, 
48:6) less abundant and others of a similar length or longer, 
with fewer double bonds being more abundant (48:0, 50:1, 
50:2).  Like the remodelling of PCs, the abundance of 
polyunsaturated species is reduced, however the average 
length of the fatty acid residues appears to be longer in TGs in 
affected systems.  A shift towards less polyunsaturated TGs may 
explain why the oxidised derivatives of TGs (TGox) are less 
abundant in affected individuals; a lower abundance of 
polyunsaturated TGs reduces the concentration of species 
prone to non-specific oxidation. 
The significant increase in the abundance of TG(51:5) and 
(53:4) in individuals who later developed GDM is consistent with 
a study of lipid metabolism in pregnant women with GDM in the 
Cambridge Baby Growth Study (CBGS) who were of 
heterogeneous BMI.  The latter study identified a higher 
abundance of TG(51:1), a species that must comprise a fatty 
acid with an odd number of carbons, as being associated with 
GDM29.  The results of the CBGS and present study contrast with 
evidence that a higher dietary intake of odd-chain-containing 
species is associated with a lower risk of T2DM74-76.  However, 
the integration of a signal that represents both PE(38:2) and 
PC(35:2) is significantly lower than in controls, suggesting that 
at least one odd-chain containing phospholipid is lower in 
participants who go on to be diagnosed with GDM.  Several or 
different lipid pathways may therefore be involved in the 
relationship between hyperglycaemia and lipid metabolism in 
GDM.  However a further study would require information on 
dietary intake during pregnancy to characterise this interaction 
in GDM. 
We also found an increase in mono-unsaturated species in 
association with GDM, e.g. TG(50:1), and a decrease in the 
abundance of species that may result from the release of mono-
unsaturated fatty acids (lyso-PC(16:0) and lyso-PC(18:1)).  A 
similar increase in abundance of PC(32:1) and TG(51:1) was 
previously found to be associated with the emergence of GDM 
in the CBGS cohort (heterogeneous for BMI)29.  These species 
may contain or may have arisen from others that contained 
FA(16:1).  Increased FA(16:1) in circulating phospholipids has 
been linked to a decrease in insulin sensitivity and increased 
adiposity77.  However, it is not clear why a greater number or 
abundance of such species should be present in obese 
individuals.  These complicated effects may be explained by the 
evidence that the metabolism and distribution of C16:1 differs; 
a higher abundance of FA(16:1) in the circulation predicts 
metabolic syndrome78, but the abundance of C16:1 in 
erythrocytes is relatively low in obese individuals79 and may 
offer protection against sudden cardiac arrest80.  Furthermore, 
infusions of FA(16:1) into obese ovines have been shown to 
reduce the size of intramuscular adipocytes and restore 
sensitivity to insulin79.  This pattern of distribution of fatty acids 
clearly has a profound effect on cardio-metabolic disease risk, 
and may have also have implications in GDM. 
The importance of how lipids and triglycerides are 
distributed between lipoproteins in obesity and diabetes is 
intriguing in the context of recent work from our group that 
shows that the structure of lipid assemblies in the circulation 
differ in obese women from the UPBEAT cohort before 
development of GDM30.  White et al. showed that the profile of 
both VLDLs and HDLs differs at the same time point as the shifts 
in lipid profile detected in this study30.  This distribution of lipids 
between lipoproteins may be important for the effect(s) those 
lipids have.  For example, the distribution may influence which 
proteins they interact with and thus their down-stream effects.  
Further work, in which lipoproteins are separated by size and 
undergo the same detailed molecular profiling as the overall 
plasma, is required to answer this question formally. 
Our data raise questions about the nature of GDM-related 
shifts in lipid abundance, the role of those lipids in vivo and 
invite comparison with shifts in lipid metabolism in the CBGS 
cohort (not selected for BMI).  In the CBGS cohort five candidate 
biomarkers changed in abundance before a diagnosis of GDM29, 
viz. TG(51:1), TG(48:1), PC(32:1), PC-O(40:3), PC-O(40:4).  Only 
the change in PC-O(40:4) is common to both studies, with the 
same trend of a lower abundance in the GDM groups.  However, 
the isoform of a triglyceride found in the present study (48:0) is 
similar to (48:1), and the (51:1) found in CBGS may contain 
similar fatty acid residues to those in the isoforms (50:1) and 
(51:5) found in the present report.   This suggests that there is 
some similarity between the shifts in lipid metabolism in 
advance of GDM between obese-only and mixed-BMI groups, 
and thus that there may be changes in lipid metabolism distinct 
from those associated with obesity. 
Molecular profiling in two studies of T2DM has shown 
associations with the abundance of lipid and triglyceride 
species81, 82.  Both demonstrate that isoforms of PC(38:6), very 
similar to the PC(38:5) identified in the present study, are more 
abundant in advance of T2DM81, 82. Other commonalities 
include the pattern of shifts in the abundance of triglycerides 
i.e. slightly larger, less unsaturated TGs are more abundant 
where slightly lighter, polyunsaturated TGs are less abundant  in 
individuals who develop either condition81.  Since similar 
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pathways appear dysregulated in T2DM and GDM, these 
relationships may underpin the association between GDM and 
the risk of T2DM post partum7, 83, 84. 
The panels of lipids found to be associated with GDM in the 
present study, in the CBGS study29, and in T2DM81, 82, are all 
notable for the considerable breadth of molecular species.  This 
raises the question of why different lipids of contrasting 
molecular classes showed significant associations, where similar 
ones did not.  One possible answer is that GDM has a range of 
aetiologies that emerge from one or more of several 
mechanisms.  If such sub-groups are identified, risk 
stratification by sub group according to risk may be desirable.  
For example, some participants had a high blood glucose 
concentration for about an hour after ingesting the sugar, 
others both a high 1h and also high glucose 2h after ingestion, 
and a third group had high blood glucose concentration in all 
three measurements and a fourth group with a high fasting 
blood glucose and a lower 1h and 2h..  It seems unlikely that a 
short-term high glucose concentration in the circulation is the 
result of profound insulin insensitivity, where a high blood 
glucose concentration over a long period of time may indicate 
this.  These responses to the OGTT may therefore reflect 
different pathophysiological pathways to hyperglycaemia in 
pregnancy.  Recent work on possible genetic determinants of 
GDM found that both insulin sensitivity and secretion were 
associated with higher genetic risk scores85, suggesting that 
such mechanisms also have a genetic basis. 
The shifts in lipid metabolism observed in the present study 
and others may therefore be the result of the sum of up- and 
down-stream effects of changes to insulin secretion and 
sensitivity, such as altered abundance of fatty acids.  A simple 
diagnosis of GDM using an OGTT may therefore describe a 
collection of aetiologies driven by one or more of related 
mechanisms.  Grouping participants from a mechanistic 
perspective may therefore offer a different insight into the 
relationship with lipid metabolism.  A finer understanding of the 
affected species in individuals who later develop GDM will 
indicate more clearly which pathways (e.g. biosynthesis of PC) 
are affected and which mechanisms (fatty acid distribution, 
oxidation of TGs) are altered.  This approach may also be useful 
in the development of personalised treatment of GDM. 
Changes in abundance of several lipids in the second 
trimester found to be related to later GDM development have 
also been identified as candidate biomarkers of higher birth 
weight in healthy pregnancies86.  This includes SM(32:1) and 
PC(35:2) (isobaric with PE(38:2)), both of which are less 
abundant in the circulation of women who deliver macrosomic 
babies from non-GDM pregnancies86.  Several isoforms of PC 
that are similar to PC(40:7) and (40:10) are similarly less 
abundant.  However, it remains to be determined what, if any, 
are the functional roles of any of the predictive candidate 
biomarkers.  Further work might focus on establishing the roles 
and distribution of the individual components identified here, 
but also how they emerge and are degraded. 
 Conclusions 
This study tested the hypothesis that phospholipid and 
triglyceride metabolism were altered by the beginning of the 
second trimester in obese pregnant women who later 
developed GDM.  Differences previously unknown in the 
abundances of lipid, sterol and triglyceride species were 
identified at least 10 weeks before diagnosis.  This produced 
evidence that several aspects of triglyceride metabolism were 
modulated, including oxidation, and was consistent with 
previous work on the lipoprotein profile30.  The modulations 
observed invite studies into the emergence of changes in lipid 
and triglyceride metabolism as either a driver of 
hyperglycaemia or as an associated but independent metabolic 
effect. The early identification of altered lipid metabolism, 
before standard diagnosis through hyperglycaemia associated 
with GDM, implies that lipid species are involved in the 
aetiology of GDM, or in the same patho-physiological pathway. 
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